Combined Effect of Omega-3 Fatty Acids and Phytosterol Ester on alleviating Hepatic Steatosis in NAFLD Subjects: A Double-blind Placebo-controlled Clinical Trial
Combined Effect of Omega-3 Fatty Acids and Phytosterol Ester on alleviating Hepatic Steatosis in NAFLD Subjects: A Double-blind Placebo-controlled Clinical Trial
复制标题
Omega-3 脂肪酸和植物甾醇酯对缓解 NAFLD 受试者肝脏脂肪变性的联合作用：双盲安慰剂对照临床试验
DOI：
10.1017/s0007114520000495
复制
发表时间：
2020
影响因子：
3.6
通讯作者：
Hongli Yan
中科院分区：
文献类型：
--
作者：
Lihua Song;Xin Gang Zhao;Peng Ling Ouyang;Qi Guan;Li Yang;Fengju Peng;Huanwang Du;Fei Yin;Wei Yan;Wen Juan Yu;Hongli Yan
本研究的目的是研究n-3脂肪酸（EPA和DHA，EPA：DHA比例为150：500）和植物甾醇酯（PS）对非酒精性脂肪性肝病（NAFLD）患者的联合作用。我们进行了一项随机、双盲、安慰剂对照试验。96名NAFLD受试者被随机分配到以下组：PS组（接受3.3 g/d PS）; FO组（接受450 mg EPA + 1500 mg DHA/d）; PS + FO组合组（接受3.3 g/d PS和450 mg EPA + 1500 mg DHA/d）和PO组（安慰剂组）。四组的基线临床特征相似。主要结果是肝脏：脾脏衰减比（L：S比）。PS + FO组肝脾增重（≤1）百分比为36%（P = 0·083），高于其他3组（PS组11%，P = 0·519; FO组18%，P = 0·071; PO组15%，P = 0·436）。与基线相比，试验结束时三个研究组的转化生长因子-β（TGF-β）均显著降低（PS，P = 0·000; FO，P = 0·002;干预结束时，FO组（P = 0·036）、PS + FO组（P = 0·005）和PO组（P = 0·032）TNF-α水平均显著降低。值得注意的是，PS + FO组中TGF-β的降低显著高于PO组（P = 0.032）。PS + FO组的TAG和总胆固醇水平分别降低了11.57%和9.55%。总之，PS和EPA + DHA的共同补充可以增加肝脂肪变性的治疗效果。
The aim of this study was to investigate the combined effect of n-3 fatty acids (EPA and DHA, at an EPA:DHA ratio of 150:500) and phytosterol esters (PS) on non-alcoholic fatty liver disease (NAFLD) patients. We conducted a randomised, double-blind, placebo-controlled trial. Ninety-six NAFLD subjects were randomly assigned to the following groups: the PS group (receiving 3·3 g/d PS); the FO group (receiving 450 mg EPA + 1500 mg DHA/d); the PS + FO combination group (receiving 3·3 g/d PS and 450 mg EPA + 1500 mg DHA/d) and the PO group (a placebo group). The baseline clinical characteristics of the four groups were similar. The primary outcome was liver:spleen attenuation ratio (L:S ratio). The percentage increase in liver–spleen attenuation (≤1) in the PS + FO group was 36 % (P = 0·083), higher than those in the other three groups (PS group, 11 %, P = 0·519; FO group, 18 %, P = 0·071; PO group, 15 %, P = 0·436). Compared with baseline, transforming growth factor-β (TGF-β) was significantly decreased in the three study groups at the end of the trial (PS, P = 0·000; FO, P = 0·002; PS + FO, P = 0·001) and TNF-α was significantly decreased in the FO group (P = 0·036), PS + FO group (P = 0·005) and PO group (P = 0·032) at the end of the intervention. Notably, TGF-β was reduced significantly more in the PS + FO group than in the PO group (P = 0·032). The TAG and total cholesterol levels of the PS + FO group were reduced by 11·57 and 9·55 %, respectively. In conclusion, co-supplementation of PS and EPA + DHA could increase the effectiveness of treatment for hepatic steatosis.